<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278443</url>
  </required_header>
  <id_info>
    <org_study_id>RD2016-50</org_study_id>
    <nct_id>NCT04278443</nct_id>
  </id_info>
  <brief_title>Fertility After Prostate Brachytherapy</brief_title>
  <official_title>A Single Site Prospective Descriptive Study on the Effect of Brachytherapy Monotherapy for Prostate Cancer on Male Fertility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East and North Hertfordshire NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BXTAccelyon Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>East and North Hertfordshire NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although brachytherapy toxicity data on erectile dysfunction, urethral dysfunction and
      bladder and bowel impact has been collected for a number of years, there is limited
      information on its effect on male fertility. This study aims to investigate the effect of
      brachytherapy on fertility
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brachytherapy is a commonly employed technique in the treatment of all prostate cancer risk
      groups. It delivers a high radiation localised to the prostate gland. The effects of this on
      fertility have not been systematically studied. An increasing number of younger men for whom
      fertility is an issue are being diagnosed with prostate cancer and may be offered
      brachytherapy amongst their treatment choices. This study therefore addresses this issue with
      a systematic evaluation of sperm count and quality before and after both high dose rate and
      low dose rate brachytherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Anticipated">August 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To define effect of prostate brachytherapy on male fertility.</measure>
    <time_frame>12 months</time_frame>
    <description>measure by sequential sperm counts</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Low dose rate brachytherapy</arm_group_label>
    <description>20 patients receiving low dose rate brachytherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose rate brachytherapy</arm_group_label>
    <description>20 patients receiving high dose rate brachytherapy.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and semen samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men undergoing brachytherapy for prostate cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  18 years or older

          -  Receiving brachytherapy monotherapy; High or Low dose rate

          -  Ability to ejaculate

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  History of infertility or vasectomy

          -  Previous chemotherapy or pelvic radiotherapy

          -  Prior use of androgen deprivation therapy

          -  5 alpha-reductase inhibitors within the last 4 months

          -  Alpha blockers within 7 days of semen collection
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Study on male fertility, thus only male participants are eligible</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Peter Hoskin</last_name>
    <phone>0203 826 2438</phone>
    <phone_ext>2438</phone_ext>
    <email>peterhoskin@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shreya Armstrong</last_name>
    <phone>0203 826 2145</phone>
    <phone_ext>2145</phone_ext>
    <email>shreya.armstrong@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>East and North Hertfordshire NHS Trust</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Hoskin</last_name>
      <phone>0203 826 2438</phone>
      <email>peterhoskin@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Lucy Collins</last_name>
      <phone>0203 826 2073</phone>
      <email>lucy.collins8@nhs.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

